JNJ vs PG: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of October 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. JNJ and PG share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined JNJ and PG exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Johnson & Johnson is one of the world's largest healthcare companies, now focused on two core areas after spinning off its consumer-health business (Kenvue). Its Innovative Medicine segment develops and sells branded prescription drugs across oncology, immunology, neuroscience, cardiovascular, and other areas, with major franchises that drive much of its profit. Its MedTech segment makes medical devices and surgical equipment for cardiovascular intervention, orthopedics, surgery, and vision care. J&J makes money by researching, manufacturing, and selling patented pharmaceuticals and devices to hospitals, physicians, pharmacies, and patients worldwide, supported by one of the largest research and development budgets in healthcare. The company is known for its diversification, financial strength, AAA-class balance sheet, and a multi-decade record of raising its dividend, making it a classic defensive blue chip. Founded in 1886 and headquartered in New Brunswick, New Jersey, J&J is a broadly held, large-cap healthcare company valued for stability, income, and a deep drug and device pipeline.

Full JNJ guide

Procter & Gamble is one of the world's largest consumer-products companies, selling everyday household and personal-care brands used by billions of people. Its portfolio is organized into segments spanning fabric and home care (Tide, Ariel, Downy, Dawn, Febreze), baby, feminine, and family care (Pampers, Always, Bounty, Charmin), beauty (Olay, Pantene, Head & Shoulders, SK-II), grooming (Gillette, Venus), and health care (Crest, Oral-B, Vicks, Metamucil). P&G makes money selling these branded products through retailers, e-commerce, and other channels worldwide, relying on scale, marketing, and continual product innovation to command premium pricing and shelf space. The company deliberately pruned its portfolio over the past decade to focus on a smaller set of large, profitable, daily-use categories. Founded in 1837 and headquartered in Cincinnati, Ohio, P&G is a classic defensive blue chip and a Dividend King, prized for steady cash flow, pricing power, and an exceptionally long record of dividend increases.

Full PG guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• JNJ drivers: Innovative Medicine pipeline; MedTech innovation and recovery.
• PG drivers: Brand strength and pricing power; Defensive, recurring demand.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: J&J faces patent expirations on key drugs, including the eventual loss of exclusivity for major franchises, which requires the pipeline to continually replace lost revenue. For PG, p&G's mature categories grow slowly, so organic growth depends on modest pricing and volume gains; in a low-inflation environment, raising prices further is harder and volumes can soften if shoppers trade down to private-label alternatives.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick JNJ if you believe its drivers more; PG if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the JNJ and PG guides.

JNJ. J&J's trailing P/E near 39 is inflated by a third quarter in which GAAP net income fell to about $210 million on items excluded from adjusted results; on forward estimates (about $11.71 of EPS for 2027) the multiple is near 22. That is a premium to where the stock traded early in 2026, after a roughly 24% year-to-date rise, and the dividend yield has compressed to about 2.1%. The market is paying for steady mid single-digit growth, high margins, strong cash generation and a raised 2026 outlook, still with some discount for litigation and patent-cliff overhangs; figures are approximate as of October 16, 2026.

PG. P&G is a high-margin, cash-rich consumer-staples leader that commands a premium valuation for its brand strength, defensiveness, and unmatched dividend record. At $159.10 in mid-October 2026 it trades around 24 times trailing and 21.5 times forward earnings while consensus calls for roughly flat EPS in fiscal 2027, so the price leans on stability and capital return rather than growth. The fiscal Q1 2027 report on October 22 (consensus EPS about $1.89 on $22.8 billion of revenue) is the next test.

Headline figures (approximate, October 2026): JNJ shows revenue (ttm) ~$99 billion, q3 2026 sales ~$25.4 billion (+~6% YoY), q3 2026 adjusted eps $2.59 (vs ~$2.52 est.), operating margin ~25%; PG shows revenue (fiscal 2026) ~$87 billion, +1.5% yoy in the June quarter, operating margin ~22%, net margin ~18% (~$16 billion net income), free cash flow ~$13.3 billion (TTM).

JNJ and PG are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined JNJ and PG exposure against your real portfolio. It is not an investment adviser.